Af­ter steer­ing Lund­beck through buy­outs, lay­offs and big ap­proval, Deb­o­rah Dun­sire will step down

Sea­soned biotech CEO Deb­o­rah Dun­sire is re­tir­ing from Lund­beck af­ter five years, mak­ing room for Charl van Zyl to step in as pres­i­dent and CEO by Oc­to­ber.

The an­nounce­ment for Dun­sire’s planned de­par­ture fol­lows a string of pos­i­tive news out of the Dan­ish drug­mak­er, in­clud­ing an FDA ap­proval for its Ot­su­ka-part­nered an­tipsy­chot­ic Rex­ul­ti for ag­i­ta­tion as­so­ci­at­ed with de­men­tia due to Alzheimer’s dis­ease — a po­ten­tial block­buster in­di­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER